Adaptimmune therapeutics plc (ADAP)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities
Net loss

-137,920

-137,165

-143,974

-99,430

-101,848

-95,514

-86,604

-92,724

-69,434

-70,138

-58,289

-75,905

-77,785

-71,579

0

0

0

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation

7,055

7,172

7,346

7,331

7,276

7,188

6,862

6,508

5,786

5,032

4,254

3,637

3,405

3,126

0

0

0

Amortization

851

838

669

651

646

622

588

536

474

391

305

237

182

160

0

0

0

Share-based compensation expense

9,022

11,053

12,244

14,466

15,009

16,202

15,301

14,458

12,790

10,804

9,952

9,037

9,433

8,821

0

0

0

Realized loss on available-for-sale debt securities

-

-

-

-

-

2,473

0

0

0

-

-

-

-

-

-

-

-

Unrealized foreign exchange gains

-4,426

-1,076

-5,348

-7,880

-12,514

-9,747

-3,208

2,478

16,409

8,599

6,257

2,516

-242

1,314

0

0

0

Other

-1

-185

-220

68

74

237

0

0

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Increase in receivables and other operating assets

-2,030

1,436

21,097

10,411

1,642

5,162

15,666

21,249

15,712

7,346

1,441

4,833

7,857

6,533

0

0

0

Increase in non-current operating assets

1,690

1,450

-1,720

-1,918

-846

-742

-3,089

-2,756

-2,009

-2,115

304

374

-369

-2,221

0

0

0

Decrease in payables

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Increase in deferred revenue

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase (decrease) in payables and deferred revenue

-

-

-

-

-

-40,923

-23,953

-1,598

5,067

12,439

20,463

10,957

13,961

16,808

0

0

0

Net cash provided by (used in) operating activities

-59,440

-112,500

-131,664

-92,117

-93,312

-104,388

-94,059

-90,509

-73,155

-54,315

-30,589

-59,444

-57,928

-48,168

0

0

0

Acquisition of property, plant and equipment

880

1,592

1,512

1,973

2,910

3,910

5,675

6,594

14,298

24,643

29,457

29,784

22,047

11,506

0

0

0

Acquisition of intangibles

1,429

1,482

1,168

1,710

993

798

747

113

137

369

543

684

660

1,279

0

0

0

Maturity of short-term deposits

-

-

-

-

-

-

-

-

-

40,625

64,525

54,573

73,238

73,377

0

0

0

Investment in short-term deposits

-

-

-

-

-

-

-

-

-

18,000

18,000

18,000

44,849

42,837

0

0

0

Maturity or redemption of marketable securities

128,998

125,303

115,853

121,645

132,664

138,038

0

0

0

-

-

-

-

-

-

-

-

Investment in marketable securities

121,347

27,284

94,322

133,214

142,201

150,787

0

0

0

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

5,342

94,945

18,851

-15,252

-13,440

-17,457

-5,057

3,752

-89,805

-126,081

-69,111

-73,119

5,682

17,755

0

0

0

Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs of $979 and $nil

0

-

-

-

-

-

-

-

-

103,167

0

0

0

-

-

-

-

Proceeds from exercise of stock options

1,224

366

470

979

1,539

3,037

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

91,774

366

470

100,632

101,192

102,690

102,586

2,794

43,705

103,568

0

0

0

-

-

-

-

Effect of currency exchange rate changes on cash, cash equivalents and restricted cash

-1,299

-372

-1,174

-793

2,215

3,335

4,216

4,316

2,382

2,328

0

0

0

-

-

-

0

Net increase (decrease) in cash and cash equivalents

36,370

-17,568

-113,517

-7,530

-3,345

-15,820

7,686

-79,647

-116,873

-74,500

4,610

-28,969

6,429

-35,975

0

0

0